Home Career Molecular profiling identifies a new subtype of high-risk liver cancer – ScienceDaily

Molecular profiling identifies a new subtype of high-risk liver cancer – ScienceDaily


Until recently, almost all childhood liver cancers were classified as hepatoblastoma or hepatocellular carcinoma. However, pediatric pathologists have noticed that some liver tumors have histological features that are difficult to match in either of these two carcinoma models. These cancers are less likely to respond to chemotherapy, and patients ’results are poor.

The first author was Dr. Pavel Sumazin, an associate professor of pediatrics at Baylor College of Medicine and the Texas Children’s Cancer and Hematology Center, and his colleagues tried to better characterize this high-risk cancer.

The researchers studied the molecular profiles of the tumors, including genetic changes and gene expression profiles. They found that these profiles did not fit into the molecular categories of hepatoblastoma (HB) or hepatocellular carcinoma (HCC). Instead, these tumors exhibited repetitive molecular features that were observed in both HBs and HCC. They designated these tumors as hepatoblastomas with signs of hepatocellular carcinoma (HBC).

The team also studied HBC treatments and outcomes and found that they tended to be more resistant to standard chemotherapy and had poor outcomes if not treated with more aggressive surgical approaches, including transplantation. Based on their findings, the team proposed a diagnostic algorithm for HBC stratification and specialized treatment guidance.

“Our results underscore the importance of molecular testing to accurately classify these tumors to optimize treatment guidelines at the time of initial diagnosis,” said Dr. Dolores Lopez-Terada, author of the article, professor of pathology, immunology and pediatrics at Baylor and head of the Techology Department of Pediatric Genomic Medicine. . “Our analysis suggested that children with HBCs may benefit from treatment strategies that differ from those recommended for patients with hepatoblastoma and hepatocellular carcinoma.”

Find all the details of this study in Journal of Hepatology.

Sumazin and Lopez-Terada are members of the Dan L. Duncan Complex Cancer Center in Baylor. Other authors from Baylor and Texas Children’s include Trisha L. Peters, Stephen F. Sarabia, Hyunja R. Kim, Martin Urbicane, Emporia Faith Hollingsworth, Carla R. Alvarez, Cynthia R. Perez, Mohammad Javad Najaf Panah, Jessica L. , Katie Skarson, Barry Zorman, Sarah E. Woodfield, John A. Goss, Sanjev A. Vasudevan, Andras Hechei, Angschumoy Roy, Kevin E. Fisher, Hookah R. Patel and Milton J. Feingold. Howard Katzenstein, Alison F. O’Neill, Rebecca Myers, Greg Qiao, Jim Geller, Saranganjan Ranganathan, Arun A. Rangoswami, all members of the Children’s Cancer Cancer Committee, as well as Rita Aladjo and Alice Poe in . They are from the following institutions: Wolfson Children’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical School, Primary Children’s Hospital, Cincinnati Children’s Hospital Medical Center, University of California at San Francisco and Bambina Gesu Children’s Hospital.

This work was funded by the Texas Institute for Cancer Prevention and Research (RP180674), the Horizon 2020 European Union (826121), the Schindler Foundation and the National Cancer Institute (R21CA223140).

Source of history:

Materials provided Baylor Medical College. The original was written by Molly Chiu. Note: Content can be edited by style and length.

Source link

Previous articleCan you solve this? Intrigue in a pet hotel Mathematics
Next articleJob prospects for recent college graduates